The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001256369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/09/2026
Date registered
Help: Date registered
15/10/2026
Date last updated
Help: Date last updated
15/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study to Evaluate the Food Effect of CBT-248 in Healthy Adult Participants
Scientific title
A Phase 1 Study to Evaluate the Food Effect of CBT-248 in Healthy Adult Participants
Additional trial identifiers [1] 318495 0
CBT-248-HV-P1
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chronic pancreatitis 343670 0
Condition category
Condition code
Oral and Gastrointestinal 339789 339789 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 339915 339915 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a single-site, randomised, double-blind, placebo-controlled, Phase 1 food-effect study to investigate the safety, tolerability, pharmacokinetics, and effect of food on CBT-248 exposure in healthy adult volunteers. CBT-248 is an oral capsule.

A total of 8 participants will be enrolled in the Cohort, A3, with 6 participants randomised to CBT-248 and 2 participants randomised to placebo. Cohort A3 uses a two-period fasted-to-fed design. Participants will receive one dose under fasted conditions in Period 1 and one dose under fed conditions in Period 2. The dose level for Cohort A3 is 1000 mg and will be administered as vegetable (cellulose) capsules.

The 1000 mg dose level will commence with 2 sentinel participants, with one participant randomised to CBT-248 and one participant randomised to placebo. Sentinel participants will be monitored in clinic for at least 24 hours after dosing, and the Principal Investigator will review available safety and tolerability data before dosing the remainder of the cohort.

Period 1 dosing will occur after an overnight fast of at least 10 hours. Period 2 dosing will occur after an overnight fast of at least 10 hours and approximately 30 minutes after starting a high-fat/high-calorie meal. The inter-period interval will be determined based on safety, tolerability, and PK review from Period 1 and protocol-defined Safety Review Committee requirements, and will be no fewer than 7 days.

The high-fat/high-calorie meal will provide approximately 800–1000 calories, with approximately 500–600 calories from fat, approximately 150 calories from protein, and approximately 250 calories from carbohydrates. An example of a standard meal is:
- Two eggs fried in butter
- Two strips of bacon
- Two slices of toast with 32 g butter
- 2 hash browns (approximately 115 g)
- 1 cup (approximately 250 mL) of full cream milk
Intervention code [1] 335395 0
Treatment: Drugs
Description of the comparator or control
The control treatment (placebo) will be a vegetable (cellulose) capsule that is visually identical to the study treatment, but it will not contain the active ingredient.

Participants in the FE group will receive two doses of Placebo, one each on Day 1 of Period 1, and Day 1 of Period 2.
Control group
Placebo

Outcomes
Primary outcome [1] 346960 0
Measure the incidence, severity, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs; including withdrawals due to AEs), measured as a composite outcome.
Timepoint [1] 346960 0
AEs will be monitored continuously from baseline (Day -1) to end-of-treatment (Day 7 of Period 2, one week after the second dose of CBT-248).
Secondary outcome [1] 468348 0
Measure how the body interacts with CBT-248 as single oral doses in fasted and fed healthy adult participants, measured as a composite outcome.
Timepoint [1] 468348 0
PK blood samples will be collected at the following time points: Period 1: Day -6; Day -2 (Admission); 1 hour pre-dose on Day 1; 5, 15 and 30 minutes post-dose; 1, 1.5, 2, 4, 6, 8, 10, 16 and 24 hours post-dose; and Day 7 (follow-up). Period 2: Day -6; Day -2 (Admission); 1 hour pre-dose on Day 1; 5, 15 and 30 minutes post-dose; 1, 1.5, 2, 4, 6, 8, 10, 16 and 24 hours post-dose; and Day 7 (follow-up).

Eligibility
Key inclusion criteria
* Adult males and females, 18 to 55 years of age (inclusive) at Screening.
* Body mass index (BMI) between 18.0 and 32.0 kg/m2 (inclusive) at Screening.
* Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities after physical examination.
* Female volunteers must be of non-childbearing potential or be willing to avoid pregnancy by using adequate contraception.
* Male volunteers must agree not to donate sperm and to use adequate contraception with female partners.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
* Known hypersensitivity to the study drug or any of the study drug ingredients, or history of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer’s ability to participate in the study.

* Clinically significant infection and/or cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the participant’s risk if they were to participate in the study.

* History or current evidence of a clinically significant breast mass, unexplained nipple discharge, suspicious breast imaging, or other findings suggestive of clinically significant breast pathology that, in the opinion of the Investigator, could increase participant risk or interfere with study participation.

*Unable or unwilling to comply with the required soy-restricted dietary periods specified in the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All study participants who sign a participant informed consent form (PICF) will receive a unique sequential number (i.e., a screening number).

Participants who meet the study eligibility criteria will be assigned a randomisation number, which corresponds to a study treatment (CBT-248 or placebo) in accordance with the randomisation schedule. Randomisation will be performed prior to dosing on Day 1. Randomisation will be performed using a paper-based randomisation schedule provided to unblinded site staff.

The randomisation schedule will be prepared by unblinded statistician(s) and will be maintained under controlled access. Blinded study staff will not have access to the randomisation schedule until after database lock.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation to CBT-248 or placebo will be performed using a block randomisation algorithm.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 323073 0
Commercial sector/Industry
Name [1] 323073 0
Cibus Therapeutics, Inc
Country [1] 323073 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Cibus Therapeutics, Inc
Address
Country
United States of America
Secondary sponsor category [1] 326019 0
Commercial sector/Industry
Name [1] 326019 0
Avance Clinical Pty Ltd
Address [1] 326019 0
Country [1] 326019 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321474 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 321474 0
Ethics committee country [1] 321474 0
Australia
Date submitted for ethics approval [1] 321474 0
02/09/2026
Approval date [1] 321474 0
13/10/2026
Ethics approval number [1] 321474 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153830 0
Dr Aarthy Joseph
Address 153830 0
Nucleus Network St Kilda Road, Level 3, 549 St Kilda Road, Melbourne, Victoria, 3004
Country 153830 0
Australia
Phone 153830 0
+61 3 8593 9801
Fax 153830 0
Email 153830 0
Contact person for public queries
Name 153831 0
Dr Aarthy Joseph
Address 153831 0
Nucleus Network St Kilda Road, Level 3, 549 St Kilda Road, Melbourne, Victoria, 3004
Country 153831 0
Australia
Phone 153831 0
+61 3 8593 9801
Fax 153831 0
Email 153831 0
Contact person for scientific queries
Name 153832 0
Honit Piplani
Address 153832 0
Cibus Therapeutics, Inc., 3160 Porter Dr, Suite 140, Palo Alto, CA 94304, United States of America
Country 153832 0
United States of America
Phone 153832 0
+1 669 300 8336
Fax 153832 0
Email 153832 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.